Prolific Machines

Prolific Machines is pioneering an optogenetic biomanufacturing platform that uses light to dynamically control cellular processes, decoupling cell growth from protein production to boost titers and improve product quality. Their technology addresses key bottlenecks in producing complex biologics like antibodies, biosimilars, and multispecifics, with demonstrated titer increases of up to 5.6-fold. The company, which is advancing through the FDA's Emerging Technology Program, offers a combination of proprietary cell lines, illumination hardware, and AI-driven bioprocess optimization as a flexible solution for therapeutic developers. By creating a new infrastructure layer for biology, Prolific aims to enable next-generation therapeutics across cell therapy and synthetic biology.

Photomolecular platform: An integrated system combining optogenetic cell line development (light-controlled gene expression), custom bioreactor illumination hardware, and AI-driven bioprocess optimization for dynamic, tunable control of bioproduction.

Competes with traditional cell line development service providers (e.g., Lonza, Sartorius) and advanced bioprocess optimization companies. Also faces competition from other novel bioproduction technologies, such as those using different gene regulation systems or continuous processing. Its unique differentiator is the use of real-time, tunable optogenetic control.